Ikarian Capital’s BridgeBio Pharma BBIO Stock Holding History

Ikarian Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.28M	Sell	57,417 -102,703	-64%	-$7.19M	0.46%	62
2026 Q1	$11.9M	Buy	+160,120	New	+$11.6M	0.97%	25
2025 Q4	–	Sell	-51,967	Closed	-$2.7M	–	184
2025 Q3	$2.7M	Buy	+51,967	New	+$2.53M	0.27%	87
2025 Q2	–	Sell	-90,837	Closed	-$3.14M	–	141
2025 Q1	$3.14M	Sell	90,837 -124,876	-58%	-$4.21M	0.39%	57
2024 Q4	$5.92M	Sell	215,713 -69,900	-24%	-$1.81M	0.81%	33
2024 Q3	$7.27M	Sell	285,613 -46,400	-14%	-$1.22M	1.01%	26
2024 Q2	$8.41M	Buy	332,013 +50,000	+18%	+$1.37M	1.47%	22
2024 Q1	$8.72M	Sell	282,013 -191,113	-40%	-$6.5M	0.96%	33
2023 Q4	$19.1M	Hold	473,126	–	–	1.79%	16
2023 Q3	$12.5M	Buy	473,126 +43,440	+10%	+$1.23M	1.5%	17
2023 Q2	$7.39M	Sell	429,686 -165,000	-28%	-$2.48M	1.18%	27
2023 Q1	$9.86M	Buy	+594,686	New	+$6.93M	2.24%	8
2022 Q1	–	Sell	-1,500	Closed	-$25K	–	201
2021 Q4	$25K	Buy	+1,500	New	+$63.5K	﹤0.01%	179
2020 Q2	–	Sell	-87,900	Closed	-$2.68M	–	179
2020 Q1	$2.55M	Buy	+87,900	New	+$2.73M	0.19%	88

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ikarian Capital's BBIO Position: Q2 2026 in Review

Ikarian Capital reduced its BridgeBio Pharma (BBIO) stake by 64% in Q2 2026, selling an estimated $7.19M and leaving 57,417 shares worth $4.28M. The position accounts for 0.46% of the portfolio, ranked #62.

Ikarian Capital first reported a position in BBIO in Q1 2020 and has held it in 14 quarters since. The position peaked at $19.1M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Ikarian Capital held 57,417 shares of BridgeBio Pharma worth $4.28M as of Q2 2026.
Ikarian Capital sold 102,703 BridgeBio Pharma shares in Q2 2026, an estimated $7.19M.
BridgeBio Pharma made up 0.46% of Ikarian Capital's portfolio in Q2 2026, its #62 holding.
Ikarian Capital first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 14 quarters since.
Ikarian Capital's BridgeBio Pharma position peaked at $19.1M in Q4 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.